




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/355, 31/35	A1	(11) International Publication Number: WO 98/38993 (43) International Publication Date: 11 September 1998 (11.09.98)
--	-----------	--

(21) International Application Number: PCT/US98/03470	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 23 February 1998 (23.02.98)	
(30) Priority Data: 60/039,790 4 March 1997 (04.03.97) US	
(71) Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION [US/US]; P.O. Box 7365, Madison, WI 53707-7365 (US).	
(72) Inventor: ELSON, Charles, E.; 7 Gray Birch Trail, Madison, WI 53717 (US).	
(74) Agent: HAAS, George, E.; Quarles & Brady, 411 East Wisconsin Avenue, Milwaukee, WI 53202-4497 (US).	

(54) Title: METHOD OF SUPPRESSING TUMOR GROWTH WITH COMBINATIONS OF ISOPRENOIDS AND STATINS



(57) Abstract

A method of inhibiting the growth of tumor cells is disclosed. In one embodiment, this method comprises the step of exposing tumor cells to an effective amount of a composition comprising at least two compounds selected from the group consisting of tocotrienols, statins and ionones.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

METHOD OF SUPPRESSING TUMOR GROWTH WITH
COMBINATIONS OF ISOPRENOIDS AND STATINS

Background of the Invention

Sundry mevalonate-derived constituents (isoprenoids) of fruits, vegetables and cereal grains suppress chemically-initiated carcinogenesis. This action has been attributed to the isoprenoid-mediated induction of detoxifying activities and to the antioxidant activity of some isoprenoids. Neither action explains the potent impact isoprenoids have on the promotion/progression stage of chemically-initiated carcinogenesis and on the growth of chemically established and implanted tumors (reviewed by Elson, 1995; Elson and Yu, 1994). Isoprenoids differ substantially in the impact they have on tumor growth. Isoprenoids suppress, via post-transcriptional actions (Correll, *et al.*, 1994; Parker, *et al.*, 1993; D.M. Peffley and A.K. Gayen, personal communication), 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase activity, the activity deemed to be rate-limiting for the synthesis of cholesterol. The statins are competitive inhibitors of HMG-CoA reductase. Correlations between the late stage tumor-suppressive potency of diverse isoprenoids and their impact on HMG-CoA reductase activity approach unity. The reductase activity of tumors differs from that of liver in being resistant to sterol feedback regulation. The tumor activity however retains high sensitivity to post-transcriptional regulation as triggered by diverse isoprenoids. As a consequence of the isoprenoid-mediated suppression of HMG-CoA reductase activity the pools of mevalonate pathway intermediates become limiting for the post-translational processing of growth-associated proteins (reviewed by Elson, 1995; Elson and Yu, 1994).

One recent review presented a list of structurally diverse isoprenoids with varying capacity to suppress mevalonate synthesis (Elson, 1995).

Summary of the Invention

In one embodiment, the present invention is a method for inhibiting tumor cell growth. The method comprises treating

-2-

the cell with a combination of at least two products of the mevalonate pathway selected from the group consisting of statins, ionones and tocotrienols.

In one preferred embodiment, the ionone is selected from 5 the group consisting of β -ionone; 6,10-dimethyl-undec-3,5-ene-2,9-dione; 6,10-dimethyl-9,10-epoxy-undec-3,5-ene-2-one; 9,10-diacetoxy-6,10-dimethyl-undec-3,5-ene-2-one; 6,10-dimethyl-9,10-diol-undec-3,5-ene-2-one and α -ionone. Preferred 10 tocotrienols include d - γ -tocotrienol, 2-desmethyltocotrienol, d - δ -tocotrienol and d -tocotrienol. Preferred statins include lovastatin, pravastatin, simvastatin and fluvastatin.

In another form, the present invention is a pharmaceutical composition for treating or preventing tumors comprising effective amounts of at least two agents selected from the 15 group consisting of tocotrienols, statins and ionones.

It is an object of the present invention to prevent or reduce tumor growth and metastasis.

It is another object of the present invention to increase 20 the duration of survival of a tumor patient following detection of tumor.

It is another object of the present invention to prevent tumor formation.

Other objects, advantages and features of the present 25 invention will become apparent to one of skill in the art after review of the specification, claims and drawings.

Description of the Drawings

Fig. 1 graphs the dose-dependent impact of tocots on the proliferation of melanoma B16 cells.

Figs. 2A and B illustrate the effects of combinations of 30 γ -tocotrienol, β -ionone and carvacrol on B16 melanoma cell populations. Fig. 2A illustrates the effects of γ -tocotrienol and β -ionone. Fig. 2B illustrates the effects of carvacrol and β -ionone.

Fig. 3 is a survival curve for host mice receiving 35 isoprenoid-enriched diets following the detection of a solid implanted B16 melanoma.

Description of the Invention

In one embodiment, the present invention is method of inhibiting the growth of tumor cells by exposing tumor cells to a combination of isoprenoids. In one embodiment of the 5 present invention, the combination comprises at least one tocotrienol and at least one ionone. In another embodiment of the present invention, the combination comprises at least one tocotrienol and at least one statin. In a third embodiment of the present invention, the combination comprises at least one statin at least one ionone. We envision that another suitable embodiment of the present invention would be a combination comprising all three products of the mevalonate pathway.

By "tocotrienol," we mean a member of the following group: The vitamin E family consists of a mixture of 15 vitamers, broadly consisting of tocopherols and tocotrienols. The tocotrienols are epimers of the corresponding tocopherols. The list below describes representative tocopherols and tocotrienols.

<i>d</i> - α -tocopherol	2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-chroman-6-ol
<i>d</i> - α -tocotrienol	2,5,7,8-tetramethyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-chroman-6-ol
<i>d</i> - β -tocopherol	2,5,8-trimethyl-2-(4,8,12-trimethyltridecyl)-chroman-6-ol
<i>d</i> - β -tocotrienol	2,5,8-trimethyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-chroman-6-ol
<i>d</i> - γ -tocopherol	2,7,8-trimethyl-2-(4,8,12-trimethyltridecyl)-chroman-6-ol
<i>d</i> - γ -tocotrienol	2,7,8-trimethyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-chroman-6-ol
<i>d</i> - δ -tocopherol	2,8-dimethyl-2-(4,8,12-trimethyltridecyl)-chroman-6-ol
<i>d</i> - δ -tocotrienol	2,8-dimethyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-chroman-6-ol
<i>d</i> -tocopherol	2-methyl-2-(4,8,12-trimethyltridecyl)-chroman-6-ol
<i>d</i> -tocotrienol	2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-chroman-6-ol
2-desmethyltocotrienol	2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-chroman-6-ol

30 Preferred tocotrienols include *d*- γ -tocotrienol and 2-desmethyltocotrienol. Other preferred tocotrienols include *d*- β -tocotrienol, *d*- δ -tocotrienol and *d*-tocotrienol.

-4-

By "ionone," we mean a member of the following group: Ionones are carotenoid-related compounds widely distributed in nature. α -Ionone and β -ionone and a number of oxygenated derivatives are widely present in plants in free and conjugated forms. Biological activities appear to be restricted to roles as phytoalexins. Ionones are also formed by thermal and photochemical mediated oxidation of carotenes.

Preferred ionones include β -ionone (4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-buten-2-one; 6,10-dimethyl-undec-3,5-ene-2,9-dione; 6,10-dimethyl-9,10-epoxy-undec-3,5-ene-2-one; 9,10-diacetoxy-6,10-dimethyl-undec-3,5-ene-2-one; and 6,10-dimethyl-9,10-diol-undec-3,5-ene-2-one. Other preferred ionones include α -ionone (4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one).

By "statin," we mean a member of the following group: The statins are derivatives of fungi metabolites (ML-236B/compactin/monocalin K) isolated from *Pythium ultimum*, *Monascus ruber*, *Penicillium citrinum*, *Penicillium brevicompactum* and *Aspergillus terreus*. These analogs of 3-hydroxy-3-methylglutaric acid (HMG), compete with HMG-CoA for the substrate binding site on HMG-CoA reductase. Statins are available by prescription in the U.S. For example, lovastatin (Mevacor/Merck), simvastatin (Zocor/Merck), pravastatin (Pravachol/Bristol-Myers Squibb) and fluvastatin (Lescol/Sandoz). There are several more under clinical investigation, including one in late-stage trials at Warner-Lambert. The more lipophilic statins have been associated with some skeletal muscle complaints (myositis, rhabdomyolysis), but most of the side-effects reported in clinical trials have been mild and tolerable (headache, abdominal pain, constipation, flatulence and diarrhea). (Pedersen, T.R., N. Engl. J. Med. 333:1350-1351, 1995; Kobashigawa, J.A., *et al.*, N. Engl. J. Med. 333:621-627, 1995.) The following list discloses some preferred statins.

	<u>Fungal derivatives</u>	<u>Trade name</u>	<u>Dosage range (mg/d)</u>	<u>Normal dose (mg/d)</u>
35	lovastatin	Mevacor	10-80	20-40
	pravastatin	Pravachol	10-40	20-40
	simvastatin	Zocor	5-40	5-10
	<u>Synthetic compound</u>			
	fluvastatin	Lescol	20-80	20-40

- 5 -

The following list describes the chemical formula of preferred statins.

5 lovastatin: [1S[1a(R),3 α ,7 β ,8 β (2S,4S),8a β]-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl-2-methylbutanoate

10 pravastatin sodium: 1-Naphthalene-heptanoic acid, 1,2,6,7,8a-hexahydro- β , δ ,6-trihydroxy-2-methyl-8-(2-methyl-1-oxybutoxy)-1, monosodium salt [1S-[1 α (β S, δ S),2 α ,6 α ,8 β (R),8a α

15 simvastatin: butanoic acid, 2,2-dimethyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2 tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl ester [1S-[1 α ,3 α ,7 β ,8 β ,(2S,4S),-8a β

20 sodium fluvastatin: [R,S-(E)]-(\pm)-7-[3(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid, monosodium salt

Preferred statins include lovastatin, pravastatin, simvastatin and fluvastatin.

The Examples below demonstrate a synergistic effect when B16 melanoma cells are treated with combinations of 15 tocotrienols, lovastatin and ionone.

In one Example below, a 68% reduction in B16 melanoma cell number (measured after 48 hours) was obtained. This represented a synergistic effect of 9% over the additive sums of the individual effects. In *in vivo* tests measuring post-20 implant survival of melanoma-bearing mice, the P-values for the three comparisons of isoprenoid versus blend treatments fall into the range of 0.66 - 0.16 whereas the P-values for the three comparisons of isoprenoid versus isoprenoid treatments are greater than 0.88. We first note that all 25 treatments significantly increased the duration of survival (P<0.03). Differences between single treatment effects were not significant. The nonparametric test P values fell between 0.64 and 0.95. When we tested the significance of differences between single treatment and blend effects the nonparametric P values fell between 0.16 and 0.64. The trend towards lower P 30 values suggests a possible synergy.

35 By "synergistic," we mean a percentage reduction in cell number of at least an additional 5% over the additive sum of individual effects or an increase in host survivability of 5% over the additive sum of individual effects.

-6-

To reach the present invention, we evaluated the tumor-suppressive potency of a number of diverse isoprenoid compounds *in vitro* and the potency of two, *d*- γ -tocotrienol and β -ionone, *in vivo*. We build on findings that isoprenoids bearing little commonality other than that of sharing a common precursor, isopentenyl pyrophosphate, suppressed melanoma cell proliferation and demonstrate that the effects of individual isoprenoids tested in binary mixtures are additive. We further report that a dietary-relevant intake of *d*- γ -tocotrienol suppressed the growth of implanted tumors.

The study described below in the Examples estimated the concentrations of structurally diverse isoprenoids required to inhibit the increase in a population of murine B 16(F10) melanoma cells during a 48 hour incubation by 50% (IC₅₀ value). The IC₅₀ values for *d*-limonene and perillyl alcohol, the monoterpenes in Phase I trials, were respectively 450 and 250 μ mol/L; related cyclic monoterpenes (perillaldehyde, carvacrol, thymol), an acyclic monoterpene (geraniol) and the end ring analog of β -carotene (β -ionone) had IC₅₀ values in the range of 120-150 μ mol/L. The IC₅₀ value estimated for farnesol, the side chain analog of the tocotrienols (50 μ mol/L) fell midway between that of α -tocotrienol (110 μ mol/L) and those estimated γ - (20 μ mol/L) and δ -tocotrienol (10 μ mol/L). A novel tocotrienol lacking methyl groups on the tocol ring proved to be extremely potent (IC₅₀, 0.9 μ mol/L). In the first of two diet studies, experimental diets were fed to weanling C57BL female mice for 10 days prior to and for 28 days following the implantation of the aggressively growing and highly metastatic B16(F10) melanoma. The isomolar (116 μ mol/kg diet) and the Vitamin E-equivalent (928 μ mol/kg diet) substitution of *d*- γ -tocotrienol for *dl*- α -tocopherol in the AIN-76A diet produced 36% and 50% retardations respectively in tumor growth (P<0.05). In the second study, melanomas were established before mice were fed experimental diets formulated with 2 mmol/kg *d*- γ -tocotrienol, β -ionone individually and in combination. A fourth diet was formulated with 4 mmol/kg *d*- γ -tocotrienol (Fig. 3). Each treatment increased (P<0.03) the duration of host survival. The present invention stems from

-7-

our finding that the effects of some individual isoprenoids were additive and the effects of other individual isoprenoids are synergistic. This finding suggests that particular combination of isoprenoids would be uniquely suitable for

5 chemotherapeutic applications.

The methods of the present invention may be realized in several embodiments. In one embodiment, the human or animal subject is administered the isoprenoid combination in a pharmaceutical or veterinary composition containing a safe and

10 effective dose. In another embodiment, the subject is fed a food that has been enriched with the isoprenoid combination. Statins are now available only by prescription and would not preferably be added to food.

The human and animal foodstuffs and pharmaceutical preparations for use in the methods of the present invention are those containing the selected isoprenoid combination additionally combined with conventional animal feeds, human food supplements or approved pharmaceutical diluents and excipients.

20 Highly active tocotrienols include *d*- γ -tocotrienol, *d*- δ -tocotrienol and 2-desmethyltocotrienol, both of which occur naturally. *d*- γ -tocotrienol and *d*- δ -tocotrienol may be extracted from tocotrienol-rich fractions of rice bran oil or of palm oil by published methods. 2-desmethyltocotrienol may

25 be extracted from tocotrienol-rich fractions of rice bran oil by published methods.

β -Ionone may be obtained from a variety of commercial sources. For example, β -ionone can be found at catalog no. W25950-0, Aldrich Flavors and Fragrances; β -ionone is also

30 listed in Aldrich Fine Chemical and Sigma catalogs. Other ionones are listed in the above catalogs and in Bedoukian Research Distinctive Perfume & Flavor Ingredients.

Lovastatin may most easily be obtained commercially.

The isoprenoid combination, in addition to being added to the subject's food, can be administered in the form of pharmaceutical or veterinary compositions such as enteric coated tablets, capsules, powders, solutions or emulsions. The precise amount to be administered will depend upon the

- 8 -

isoprenoids employed, the route of administration, the weight of the subject and the nature of the condition. We note that the melanoma cell line used for the Examples below is known to be extremely resistant to chemotherapeutic measures.

5 Therefore, the actual dosage used in patient treatment may be less than that proposed from our experimental model.

Generally, the quantities of the agents required in a pharmaceutical combination will provide a daily intake substantially less than the quantities required when the 10 agents are administered individually. Perillyl alcohol, an isoprenoid in clinical evaluation for efficacy as antitumor agents tumor therapy, is administered at levels in excess of 8 g/day; lovastatin is clinically effective, but poorly tolerated, for treating brain tumors at doses ~2 g/d (>20x the 15 dose administered for hypercholesterolemia). The tocotrienols effectively lower cholesterol levels when consumed at dose levels of <300 mg/day. Due to the synergistic actions of the agents, we anticipate a preferable blend will contain 250 mg tocotrienol/2000 mg ionone/150 mg statin (~2 mg/kg body wt.) 20 per day. A maximal preferred dosage would contain 500 mg tocotrienol/4000 mg ionone/300 mg statin per day.

A representative pharmaceutical enteric coated tablet has the formula:

Active principles:

25	d- γ -tocotrienol	50 mg
	6,10-dimethyl-9,0-epoxy-undec-3,5-ene-2-one	400 mg
	statin	30 mg

Excipients/fillers

30	Microcrystalline cellulose	
	Sodium starch glycolate	
	Corn starch	
	Hydrogenated vegetable oil wax	
	Magnesium stearate	
	Talc	

35 The preferred normal per diem dosage is 5 tablets.

A bar or cookie may be of any desired type which is prepared first and afterwards dosed with a small amount of liquid containing the active principles:

- 9 -

<i>d</i> - γ -tocotrieno	150 mg
6,10-dimethyl-9,0-epoxy-undec-3,5-ene-2-one	400 mg

It is preferable that suitable flavorings are present in the bar or cookie to impart an acceptable level of 5 palatability. It is essential that the active principles are added after any baking or heating process has occurred and cooling is complete since the tocotrienols are heat labile. Such a bar or cookie may advantageously be packed in a hermetically sealed packet.

Because the tocotrienols and ionones are relatively non-toxic, doses larger than the higher figure stated above may be administered if desired, particularly with the enteric coated 10 composition. Higher doses may, however, markedly reduce gut flora and lead to gastrointestinal disturbances. It is 15 recommended that when the compositions of the instant invention are administered, the daily intake of vitamin E is restricted. The more lipophilic (fat loving) statins have been associated with some skeletal muscle complaints (myositis, rhabdomyolysis), but most of the side effects 20 reported in clinical trials have been mild and tolerable (headache, abdominal pain, constipation, flatulence and diarrhea. Patients (Thibault, *et al.*, Clinical Cancer Research 2:483-491, 1996) tolerated intakes approaching 2 g/d (25 mg/kg body wt).

It will be apparent to those skilled in the art that 25 numerous modifications or changes may be made without departing from the spirit or the scope of the present invention. Thus, the invention is only limited by the following claims.

30

EXAMPLES

Abbreviations used: HMG CoA, 3-hydroxy-3-methylglutaryl 35 coenzyme A; IC₅₀, the concentration required to suppress the increase in the population of melanoma cells by 50%; TRF, tocotrienol-rich fraction of palm oil; TRF₂₅, oryzanol-free tocotrienol-rich fraction of rice bran oil.

-10-

A. Materials and Methods

Isoprenoids: d-Limonene (97%), perillyl alcohol (99%), perillaldehyde (92%), carvacrol (98%), thymol (98%), β -ionone (96%), geraniol (98%), farnesol (96%) and dl- α -tocopherol (97%) were purchased from Aldrich Chemical, Milwaukee, WI. An abridged list of concentrated natural sources and aroma characteristics of these isoprenoids appears below in Table 1. A preliminary study revealed the very potent tumor-suppressive action of the oryzanol-free tocotrienol-rich fraction of rice bran oil (TRF₂₅) prepared by molecular distillation (Dr. Laxman Singh, Vitamins, Inc., Chicago, IL). The fraction consisted of 6% d- α -tocopherol, 12.5% d- α -tocotrienol, 21% d- γ -tocotrienol, 10% d- δ -tocotrienol, 4.5% d-tocotrienol, 17% d-2-desmethyl tocotrienol, 18% unidentified tocotrienol isomers and 10% sterols and triglycerides (Qureshi, *et al.*, unpublished data). The major constituents, d- α -tocotrienol, d- γ -tocotrienol, d- δ -tocotrienol, and d-2-desmethyl tocotrienol, were isolated by Advanced Medical Research, Madison, WI. A chromatographic procedure was developed to separate d- γ -tocotrienol from the tocotrienol-rich fraction (TRF) of palm oil (36% d- γ -tocotrienol, 18% d- α -tocotrienol, 12% d- δ -tocotrienol and 22% d- α -tocopherol), a gift of the Palm Oil Research Institute of Malaysia, Kuala Lumpur, Malaysia. Silica gel (Merck, 60 μ , 150 g) suspended in hexane was poured into a 350 mL glass funnel with a fritted disc. The gel was washed with one L hexane prior to being loaded with 5 g of the TRF in 20 mL hexane. The tocots were eluted with the sequential applications of 500 mL mixtures of diethyl ether (5%, 10%, 12%, 14%, 16%, 18%, 20%, 22%, 25% and 30%) in hexane. The elution of each application of solvent into a filter flask was speeded by the application of vacuum produced by water aspiration. The eluates were taken to dryness under vacuum, the residues redissolved in hexane and identified according to retention time and absorption profile using an analytical HPLC system. The fraction eluted with 18% diethyl ether was predominantly (98%) d- γ -tocotrienol.

IC₅₀ Determinations: Murine B16(F10) melanoma cells, a tumor cell line with high metastatic potential (Tsukamoto, *et*

-11-

al., 1991) obtained from Dr. William B. Ershler, were grown in monolayer culture (35 x 10 mm flasks) in 3 mL RMPI 1640 media (Sigma) supplemented with 10% newborn calf serum (GIBCOBRL, Grand Island, NY) and 80 mg/L gentamycin (Sigma, St. Louis, MO). Cultures, seeded with $1-1.5 \times 10^5$ cells, were incubated for 24 hours at 37°C in a humidified atmosphere of 5% CO₂. Isoprenoids, dissolved in absolute ethanol, were added at 24 hours (0 time); all cultures contained 5 mL ethanol/L (85 μ mol/L). The cultures were incubated for an additional 48 hours. The media was removed and the monolayers were washed twice with Hanks' Balanced Salt Solution (Sigma) and then incubated with a trypsin-EDTA solution (Sigma) at 37°C for 2 minutes. Trypsin was inactivated by suspending the cells in medium containing 10% fetal bovine serum (Sigma). The cells were pelleted at 250xg and resuspended in Hanks' Balanced Salt Solution. Viable cells, cells that excluded 0.4% trypan blue (GIBCOBRL), were counted with a hemocytometer; 24 hour cell counts were deducted from final cell counts to provide an estimate of the net increase in cell number. The calculation of the concentration of an isoprenoid required to inhibit the net increase in the 48 hour cell count by 50% (IC₅₀) is based on plots of data from three or more evaluations.

Animal Studies: This evaluation of the tumor-suppressive potency of diverse isoprenoids was extended with two dietary studies. The first examined the impact of a diet-relevant intake of *d*- γ -tocotrienol on the growth of B16(F10) melanomas in host mice. The second study evaluated the impact of pharmacological intakes of *d*- γ -tocotrienol and β -ionone on the post-implant survival of melanoma-bearing mice. We first prepared a basal diet mix, patterned after the AIN-76A formulation (American Institute of Nutrition, 1977) but free of corn oil and *dl*- α -tocopherol. These ingredients and Vitamin E-stripped corn oil were purchased from Teklad Test Diets, Madison, WI. Stock solutions of *dl*- α -tocopherol (80 μ mol/g) and *d*- γ -tocotrienol (80 μ mol/g) were prepared with vitamin E-stripped corn oil. Stock solutions of the tocots, diluted with vitamin E-stripped corn oil, were mixed with the basal diet to provide finished diets containing 5% corn oil.

-12-

and specified tocol concentrations. Where noted, β -ionone was added to the oil. The diets, mixed weekly, were stored under refrigeration. Food cups were cleaned and refilled daily.

Experiment 1: Weanling C57BL female mice (Harlan-Sprague Dawley, Madison, WI) were housed in groups of four on wood shavings in plastic cages and maintained at 25°C with a 12 hour light-dark cycle. The four groups of mice (20/group) were fed experimental diets for 10 days prior to and for 28 days following the implantation of B16 melanoma cells. The split plot design consisted of four treatments comprised of two tocols, *dl*- α -tocopherol and *d*- γ -tocotrienol, each presented at two levels, 116 and 924 μ mol/kg diet. This design permitted two comparisons of diets equal in tocol content and one comparison of diets about equal in *d*- α -tocopherol equivalents. Lacking a definitive estimate of the biological activity of *d*- γ -tocotrienol, we considered reports that the 2, 5, 8 (*d*- β -) and 2, 7, 8 (*d*- γ -) trimethyl tocopherols have similar oxygen scavenging activity (maximally 66% that of the 2, 5, 7, 8 (*d*- α -) tetramethyl tocopherol) and as a class, the tocotrienols have 5 - 30% of the biological activity of the tocopherols (Karnal-Eldin and Appelqvist, 1996) in developing the rough estimate that *d*- α -tocopherol has, minimally, 6-fold the biological activity of *d*- γ -tocotrienol. We then corrected for the biological activity of the *dl*- α -tocopherol mixture (70% of the activity of *d*- α -tocopherol) in arriving at the 8:1 tocotrienol/tocopherol ratio used in formulating the experimental diets. Melanoma cells, cultured and harvested as previously, described (Shoff, et al., 1991), were washed twice with RPMI 1640 containing 10% Fetal Bovine Sera (GIBCOBRL). The pelleted cells were suspended in RPMI 1640 and counted (98% viable) after a 1:20 dilution in 0.4% trypan blue. The cells were further diluted in RPMI 1640 (1×10^8 cells/L) and 0.1 mL of the suspension (1×10^4 cells) was injected subcutaneously into the flank of each mouse. The study was terminated day 28 when the first mouse, a mouse in the control group, died. The mice were killed by CO₂ overdose and the tumors were excised and

-13-

weighed. The protocol was reviewed and approved by College of Agricultural and Life Sciences Animal Care Committee.

Experiment 2: Weanling female C57BL female mice (n=60, Harlan Sprague-Dawley) were acclimated to the housing conditions and AIN-76A diet (116 μ mol dl- α -tocopherol/kg diet) as described above. Tumors were implanted and the mice continued to receive the AIN-76A diet. Beginning on day 8 post-implant the mice were palpated daily for the presence of a tumor. Tumors were first detected on day 14. Random numbers were generated for assigning each mouse in a sequential subset of five to a diet. Experimental treatments provided 2 and 4 mmol d- γ -tocotrienol/kg diet. We additionally tested the impact of β -ionone (2 mmol β -ionone/kg AIN-76A diet) and that of a blend of the two isoprenoids (2 mmol each/kg diet) on the survival of the mice. The mice were continued on the respective experimental diets; moribund mice, identified by the Research Animal Resource-trained supervisor blinded to the experimental design, were killed by CO₂ overdose and the tumors were excised and weighed. The protocol was reviewed and approved by College of Agricultural and Life Sciences Animal Care Committee.

Statistical Methods: StatView and SuperANOVA software (Abacus Concepts, Berkeley, CA) were used for the assessment of treatment-mediated effects. Treatment-mediated differences in body and tumor weights, days to tumor appearance and days to morbidity were identified with split plot analysis of variance and pairwise t-tests of least squares means. Treatment-mediated differences in days to morbidity were also assessed using parametric (paired t-test) and nonparametric (Wilcoxon signed rank) tests (Haycock, *et al.*, 1992).

B. Results

Fig. 1 is a representative evaluation of the dose-dependent impact of five different tocots on the proliferation of melanoma B16 cells. Cultures (3 mL) seeded with 1-1.5 x 10⁵ cells were incubated for 24 hours prior to the introduction of the tocots. Viable cells were counted at 48 hours following the addition of the tocots. The cell count at

-14-

24 hours (0 time) is shown by the dashed line. The intersection of the solid horizontal line and the line plotted for each tocol indicates the concentration at which the tocol suppressed by 50% the increase in cell number during the 5 incubation (IC₅₀ value). IC₅₀ values (mean, SD and n) for all isoprenoids tested are listed on Table 1. Referring to Fig. 1, dl- α -Tocopherol had no impact on cell number. The growth-suppressive potency of the individual tocotrienols was inverse to the number of methyl groups on the 6-chromanol ring: d- α -10 tocotrienol (methyl groups at carbons 5, 7, 8 and 2) << d- γ -tocotrienol (methyl groups at carbons 7, 8 and 2) < d- δ -tocotrienol (methyl groups at carbons 8 and 2) << d-2-desmethyl tocotrienol (no methyl groups) (Table 1).

Within this series of tocotrienols the IC₅₀ value was 15 inversely related to the number of methyl groups on the 6-chromanol ring. Similarly, the IC₅₀ values calculated from plots for the more polar monoterpenoid alcohols, perillyl alcohol ([R]4-isopropenyl-1-methanol-cyclohexene), perillaldehyde ([R]-4-isopropenyl-1-carboxaldehyde 20 cyclohexene), thymol (5-methyl-2-isopropylphenol), carvacrol (5-isopropyl-2-methylphenol) and geraniol (trans 3,7-dimethyl-2,6-octadien-1-ol) were much lower than that for d-limonene ([R]4-isopropenyl-1-methyl-1-cyclohexene). The IC₅₀ value for β -ionone, the end ring analog of β -carotene, matched those of 25 the more polar monoterpenes (Table 1). The IC₅₀ for farnesol (trans, trans 3,7,11-trimethyl-2,6,10 dodecatrien-1-ol), a sesquiterpene and a structural analog to the side chain of the tocotrienols, fell midway between those of d- α -tocotrienol and d- γ - and d- δ -tocotrienol.

30 The first dietary study evaluated the impact of d- γ -tocotrienol and dl- α -tocopherol on days to detection of a solid tumor and growth of implanted B16 melanomas. As noted above the design permitted two comparisons of treatments providing equal tocol concentration (116 and 928 μ mol/kg diet) 35 and one comparison of treatments providing about 80 μ mol d- α -tocopherol equivalents (35 mg)/kg diet. At the time of tumor implant the body weight of mice receiving the high tocopherol diet was significantly lower than that of mice receiving the

-15-

low tocol diets (Table 2). At 28 days post-implant the melanomas accounted for 15% of the weight of mice receiving the AIN-76A diet. Two tocols were tested, each at two levels. The split plot analysis of variance showed the effects of tocols ($P<0.001$) and levels ($P<0.04$) on 28 day tumor weight were significant; there was no evidence of an interaction between the two factors ($P<0.77$). Least mean squares analyses confirmed the tumor growth-suppressive action of γ -tocotrienol (Table 2). The other measure of tumor growth, days post-implant to tumor detection showed tocol ($P<0.03$), level ($P<0.01$) and the interaction ($P<0.02$) to be significant. The least mean squares analysis showed that the effect of the treatment providing $928 \mu\text{mol } d\text{-}\gamma\text{-tocotrienol/kg diet}$ on this measure of tumor growth differed significantly from the effects of the other treatments.

We next determined that the effects of the isoprenoids on the growth of B16 melanoma cells in culture are additive, and in some cases, synergistic. Fig. 2A illustrates the additive effects of γ -tocotrienol and β -ionone on B16 melanoma cell populations. Values are means \pm SD, $n=28$; pooled SEM = 36 ($\times 10^4$). Cell counts calculated to show the decreased population relative to the control are listed on the insert table.

Fig. 2B illustrates the additive effects of carvacrol and β -ionone on B16 melanoma cell populations. Values are means \pm SD, $n=28$; pooled SEM = 62 ($\times 10^4$). Cell counts calculated to show the decreased population relative to the control are listed in the inset table.

a-h Means not sharing a superscript (a>b>c>d>e>f>g>h) are different ($P<0.001$). Referring to Fig. 2, B16 melanoma cells were incubated with β -ionone and $d\text{-}\gamma\text{-tocotrienol}$ in one test (Fig. 2A). $d\text{-}\gamma\text{-Tocotrienol}$ ($7.5 \mu\text{mol/L}$) and β -ionone ($50 \mu\text{mol/L}$) reduced the 48 hour cell count by 19% and 10% respectively (Fig. 2A). The 34% reduction in cell number achieved with the paired isoprenoids exceeded the 29% reduction predicted by the sum of the individual effects (Fig. 2A, inset). At higher concentrations $d\text{-}\gamma\text{-tocotrienol}$ ($15 \mu\text{mol/L}$) and β -ionone ($100 \mu\text{mol/L}$) reduced the 48 hour cell

-16-

count by 34% and 16% respectively; the additive effect, a 68% reduction in cell number, was also greater than the sum of the individual effects (59%) (Fig. 2A, inset).

Whereas the foregoing results pointed to a synergistic action of *d*- γ -tocotrienol and β -ionone, the study pairing carvacrol and β -ionone revealed only an additive effect (Fig. 2B). Carvacrol (50 μ mol/L) and β -ionone (75 μ mol/L) reduced the 48 hour cell count by 25% and 31% respectively; the additive effect, a 48% reduction in cell number, was less than the 56% reduction predicted by the sum of the individual effects. Carvacrol (100 μ mol/L) and β -ionone (150 μ mol/L) reduced the cell count by 35% and 65% respectively; the additive effect, an 84% reduction in cell number, again was less than the 100% reduction predicted by the sum the individual effects (Fig. 2B, inset). The reduction in cell number predicted by the sum of the individual effects of the isoprenoids was highly correlated with that achieved with the paired isoprenoids ($r=0.91$, $n=8$, $P<0.01$).

We then asked if either dietary *d*- γ -tocotrienol or β -ionone would prolong the survival of mice bearing implanted melanomas. Dietary treatments were initiated following the detection of solid tumors. We also asked whether these structurally diverse isoprenoids would have an additive effect on survival. The experimental groups were constructed by random assignment of each member of successive subsets of 5 mice to one of the experimental diets. Time to tumor detection did not vary between groups (Table 3). Treatments increased median duration of survival by $42 \pm 4.5\%$ and the mean duration of survival by 30% ($P<0.005$); differences between duration of survival means of the experimental groups were not significant (Table 3, Fig. 3). Fig. 3 is a survival curve for host mice receiving isoprenoid-enriched diets following the detection of a solid implanted B16 melanoma. Mean survival durations are presented on Table 4. β -ionone and γ -tocotrienol¹ treatments provided 2 mmol of the isoprenoid/kg diet; the blend provided 2 mmol of each isoprenoid/kg diet; and γ -tocotrienol² provided 4 mmol γ -tocotrienol/kg diet.

-17-

According to the experimental design, each animal within a subset of 5 could be paired with another member of the subset for testing. P-values for the pairwise comparisons, assuming normal and anormal distributions, are listed on Table 4. All analyses revealed highly significant differences between the control and treatment group means; differences between the treatment group means were not significant. Lending additional creditability to the results of the *in vitro* analysis showing an at least additive effect of the two isoprenoids is the trend shown on Table 4. Whereas the P-values for the three comparisons of isoprenoid versus isoprenoid treatments are greater than 0.88, the P-values for the three comparisons of isoprenoid versus blend treatments fall in the range 0.66 - 0.16.

15 C. Discussion

The B16 (F10) melanoma provides a rigorous model for assessing, *in vitro* and *in vivo*, the potency of pharmacological agents (Gruber, *et al.*, 1992; Kuwashima, *et al.*, 1990; Mac Neil, *et al.*, 1992; Tsukamoto, *et al.*, 1991; Shoffy, *et al.*, 1991). We now report that a diet providing an intake of 0.4 μ mol *d*- γ -tocotrienol/d suppressed the growth of the B16 melanoma implanted in the flank of host mice. In our more rigorous test, a diet providing 7 μ mol *d*- γ -tocotrienol or β -ionone/d suppressed the growth of established B16 melanomas. In *vitro* tests provided evidence of the additive effects of these two isoprenoids (Fig. 2A, B). The diet providing an intake of 7 μ mol *d*- γ -tocotrienol/d increased the duration of survival by 35%. Whereas doubling the intake of *d*- γ -tocotrienol to 14 μ mol/d did not further increase the duration of survival (-0.21 d, P=0.95), adding an intake of 7 μ mol of β -ionone to that of 7 μ mol *d*- γ -tocotrienol/d tended to increase the duration of survival (+0.83 d, P=0.65, Tables 3, 4). This study evaluated the responses of established implanted melanomas to β -ionone and *d*- γ -tocotrienol, two isoprenoids with structural relationships to the two antioxidant nutrients recently discounted as having tumor-suppressive actions (Greenberg and Sporn, 1996). Both

-18-

isoprenoids significantly increased survival time (Table 4). We note findings that a massive intake of ascorbic acid (733 μ mol/d) suppressed the growth of implanted B16 melanomas (Meadows, *et al.*, 1991). Our studies showed that a diet 5 providing an 8-fold elevation in *d*- α -tocopherol equivalents had a marginal impact on tumor growth whereas a *d*- γ -tocotrienol diet providing only the *d*- α -tocopherol-equivalent of the AIN-76A diet yielded a highly significant suppression of tumor growth.

10 D. Synergistic Action of Lovastatin, Tocotrienol and Ionone
i. Background

Lovastatin, a fungal antibiotic, competitively inhibits 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase activity (J.L. Goldstein and M.S. Brown, *Nature* 343:425-430, 15 *β*-Ionone (S.G. Yu, *et al.*, *J. Agric. Food Chem.* 42:1493-1496, 1994) a pure isoprenoid, and related agents suppress HMG CoA reductase activity via the suppression of its synthesis (reviewed in H. Mo, *et al.*, *Nutritional Oncology*, D. Huber & G. Blackburn, eds. Academic Press, NY, in press; C.E. 20 Elson, *et al.*, *Amer. Assoc. Cancer Res.*, in press). The tocotrienols, a group of mixed isoprenoids, suppress reductase activity by triggering the proteolytic degradation of the enzyme (C.E. Elson, *supra*, in press). As a consequence of the inhibited reductase action, lovastatin and later derivatives 25 (J.L. Goldstein and M.S. Brown, *supra*, 1990; R.A. Parker, *et al.*, *J. Biol. Chem.* 268:11230-11238, 1993), *β*-ionone and related pure isoprenoids (S.G. Yu, *et al.*, *supra*, 1994; H. Mo, *et al.*, *supra*, in press), and the tocotrienols (H. Mo, *et al.*, *supra*, in press; R.A. Parker, *et al.*, *supra*, 1993; A.A. 30 Qureshi, *et al.*, *J. Biol. Chem.* 261:10544-10550, 1986; A.A. Qureshi, *et al.*, *Proceedings of the 1996 PORIM International Palm Oil Conference*, Kuala Lumpur, Malaysia, pp. 168-180, 1996) lower serum cholesterol levels. Cells treated with lovastatin have a several-fold increase in HMG CoA reductase, 35 an increase resulting in an elevated reductase activity following the removal of the inhibitor (J.L. Goldstein and M.S. Brown, *supra*, 1990). Cellular activities underlying the

-19-

increase in reductase mass include increases in the transcription and efficiency of processing of HMG CoA reductase mRNA and a decrease in the proteolytic degradation of the enzyme. β -Ionone (S.G. Yu, *et al.*, *supra*, 1994) and the tocotrienols (R.A. Parker, *et al.*, *supra*, 1993) attenuate the degree of elevation in reductase activity (S.G. Yu, *et al.*, *supra*, 1994) and mass (R.A. Parker, *et al.*, *supra*, 1993) effected by lovastatin treatment.

Mevalonate pathway intermediates are essential for the post-translational modification of proteins that play essential roles in cell proliferation (see H. Mo, *et al.*, *supra*, *in press*). The competitive inhibition of mevalonate synthesis imposed by the statins suppresses the proliferation of cultured cells (J.L. Goldstein and M.S. Brown, *supra*, 1990) and the growth of implanted tumors (W. Maltese, *et al.*, *J. Clin. Invest.* 76:1748-1754, 1985; J.P. Jani, *et al.*, *Invasion Metastasis* 13:314-324, 1993). A five-year follow-up of 745 hypercholesterolemic patients receiving lovastatin, up to 80 mg/d, revealed a 33% reduction in cancer incidence (14 observed, 21 predicted) (J.A. Tolbert, *Arch. Intern. Med.* 153:1079-1087, 1993). A Phase I trial evaluated the tolerability of lovastatin administered at progressively higher doses (3 to 43 cycles of 7-day courses given monthly) involving 88 patients with solid tumors (39 with brain tumors, 24 with hormone-independent prostate cancer). Doses ranged between 2 and 45 mg/kg (the maximum dose for hypercholesterolemia is 80 mg/d). Sixty patients experienced a total of 128 episodes of toxicity; the incidence and severity of toxicity increased markedly once the 25 mg/kg dose level was reached. To prevent myotoxicity and improve the tolerability of lovastatin, ubiquinone was administered to a cohort of patients receiving 30 mg/kg or higher doses of lovastatin. Ubiquinone did not decrease the incidence of musculoskeletal toxicity but significantly decreased its severity. The authors conclude with the suggestion that high-grade gliomas represent a reasonable target for Phase II trials and recommended that alternative treatment schedules aimed at achieving sustained

-20-

inhibition of mevalonate synthesis be investigated (A. Thibault, *et al.*, *Clin. Cancer Res.* 2:483-491, 1996).

ii. *Ionone, Tocotrienol and Lovastatin Act Synergistically to Inhibit Tumor Cell Growth*

5 β -Ionone, γ -tocotrienol and lovastatin are known to individually suppress the proliferation of murine melanoma B16/F10 cells. IC₅₀ values for β -ionone and γ -tocotrienol are 140 μ mol (L. He, *et al.*, *J. Nutr.* 127:668-674, 1997), and 20 μ mol/l (L. He, *et al.*, *supra*). Using the protocol outlined in 10 He, *et al.*, *supra*, we have determined that B16 cells incubated with 1.9 \pm 0.3 μ mol/l lovastatin grow at 61.4 \pm 4.6% the rate of controls. This value confirms the value determined using a colony formation assay (J.P. Jani, *et al.*, *supra*, 1993). *In* vivo studies show that lovastatin (50 mg/kg) administered ip 15 on alternate days (J.L. Goldstein and M.S. Brown, *supra*, 1990), β -ionone (2 mmol/kg diet) (L. He, *et al.*, *supra*, 1997) and γ -tocotrienol (116-2000 μ mol/kg diet) individually suppressed the growth implanted murine melanoma B16F10 tumors.

20 Our *in vitro* assays record synergy between the growth suppressive actions of the three agents. The growth-suppressive action of each combination is greater than that predicted by the sum of the individual effects (Table 5).

25 Table 5 tabulates the results of our *in vitro* assays. Table 5 lists various concentrations of lovastatin, β -ionone and γ -tocotrienol and the growth suppressive ability of each treatment. Growth in treated cells is recorded as % of control growth. On Table 5 we show that 2 μ M lovastatin and 150 μ M β -ionone respectively decreased cell growth by 50% and 32% (50% and 68% of control growth)--the combined action of 30 the two compounds is predicted to suppress growth by 82% (50% + 32%) or reduce cell growth to 18% of control. Growth was reduced by 90% or to 10% of control. In a series of tests combining lovastatin with an isoprene (tocotrienol or ionone) we predicted a 66% reduction in cell count (33 \pm 5% of control). 35 However, we observed an 87% decrease (13 \pm 4% of control). Combinations of isoprenoids yielded a 50% reduction in cell growth--the predicted reduction was 57 (50% of control predicted, 43% of control obtained).

-21-

One will note that in each combination of lovastatin, β -ionone and tocotrienol, the combination resulted in less cell growth than the predicted, additive value.

Referring to Table 5, we would predict a full suppression of growth with a blend providing 2 μ M lovastatin, 5 μ M tocotrienol and 50 μ M ionone.

-22-

APPENDIX 1 - TABLES

Table 1. The concentrations of selected isoprenoids required to suppress the increase in the population of melanoma cells by 50% during a 48 hour incubation¹. Also listed are representative sources and aroma characteristics of each isoprenoid.

Isoprenoid Class	n μmol/L	IC ₅₀	Representative Source	Aroma
Monoterpenes				
d-Limonene	3	450±43	Citrus Peel, Mint	lemon
Perillyl alcohol	3	250±28	Citrus Peel, Mint, Sage, Lavender	lilac
Geraniol	3	150±19	Citrus Peel, Basil, Rosemary	fruit
Perillaaldehyde	3	120±17	Citrus, Basil, Rosemary	fruit
Carvacrol	3	120±15	Thyme, Marjoram, Mint, Dill	mint
Thymol	3	120±15	Thyme, Oregano, Tangerine Peel	thyme
Sesquiterpenes				
Farnesol	2	50	Rose, Chamomile, Lavender, Lilac	lilac
β-Ionone	5	140±23	Grapes, Corn, Apricots, Prunes	woody
Tocols				
d-α-Tocotrienol	4	110±15	Barley, Rice, Oat Palm, Olive Oils	oily
d-γ-Tocotrienol	6	20±3	Barley, Rice, Oat Palm, Olive Oils	oily
d-δ-Tocotrienol	3	10±3	Barley, Rice, Oat Palm, Olive Oils	oily
d-2-desmethyl Tocotrienol	3	0.9±0.2	Rice Bran	oily
d/d-α-Tocopherol	4	> 1600	Soybean, Corn, Wheat Barley, Rice, Oats, Palm Oils	oily

¹ Values are means ± SD.

Table 2. Impact of d-γ-tocotrienol on days to detection and 28-d growth of B16 melanomas implanted into the flanks of mice¹.

Tocol	μmol/kg	body weight		tumor		liver
		diet	10 d	38 d	detection	
		(g)	(g)		(d)	
d/d-α-Tocopherol	116	17.33 ^a	23.30	19.55 ^b	3.59 ^a	1.18 ^a
d-γ-Tocotrienol	116	17.02 ^a	22.43	19.68 ^b	2.31 ^{bc}	1.12 ^{ab}
d/d-α-Tocopherol	928	16.41 ^b	22.53	19.75 ^b	2.89 ^{ab}	1.06 ^b
d-γ-Tocotrienol	928	16.83 ^a	22.56	22.90 ^a	1.78 ^c	1.03 ^b
pooled SEM		b 0.10	0.19	0.35	0.17	0.02
		a>b		a>b	a>b>c	a>b

^{a-c} Means not sharing a superscript are different (P < 0.05).

¹ Values are means, n=20.

² Days post implant for appearance of a palpable tumor.

Table 3. Impact of isoprenoid-enriched diets on the duration of survival of host mice bearing established melanomas¹.

- 23 -

Group	d- γ -Tocotrienol	β -Ionone	Days to	Days survival	
	mmol/kg diet		tumor	Mean	Median
Control	0	0	15.00	13.83 ^b	15.0
d- γ -Tocotrienol ¹	2	0	14.92	18.67 ^a	20.0
d- γ -Tocotrienol ²	4	0	14.92	18.46 ^a	22.0
β -Ionone	0	2	14.92	18.27 ^a	23.0
Blend	2	2	14.92	19.50 ^a	20.5
pooled				0.547	
SEM				a>b	

^{a-b} Means not sharing a superscript are different (P<0.03).

¹ Values are means, n=12.

Table 4. Pairwise comparisons of isoprenoid effects on the duration of survival following detection of a B16 melanoma in the flanks of mice.

Group Comparison	Paired t-test		Wilcoxon Signed Rank	
	t-value	P-value	Z-value	P-value
Control vs.				
d- γ -Tocotrienol ¹	5.74	0.01	-2.93	0.01
d- γ -Tocotrienol ²	2.70	0.02	-2.22	0.03
β -Ionone ³	2.81	0.02	-2.18	0.03
Blend ⁴	3.27	0.01	-2.45	0.01
d- γ -Tocotrienol ¹ vs.				
d- γ -Tocotrienol ²	0.46	0.66	-0.47	0.64
β -Ionone ³	0.06	0.95	-0.15	0.88
Blend ⁴	0.46	0.66	-0.47	0.64
d- γ -Tocotrienol ² vs.				
β -Ionone ³	0.11	0.92	-0.06	0.95
Blend ⁴	1.36	0.21	-1.42	0.16
β -Ionone ³ vs.				
Blend ⁴	0.93	0.37	-0.83	0.41

¹ 2 mmol d- γ -tocotrienol/kg diet.
² 4 mmol d- γ -tocotrienol/kg diet.
³ 2 mmol β -ionone/kg diet.
⁴ 2 mmol d- γ -tocotrienol + 2 mmol β -ionone/kg diet.

-24-

Table 5

Lovastatin	β -Ionone	γ -Tocotrienol	Growth	Predicted
	$\mu\text{mol/L}$		% of Control	
2	0	0	50	
0	150	0	68	
2	150	0	10	18
2	0	0	60	
0	0	5	90	
0	0	10	85	
2	0	5	32	50
2	0	10	20	45
1.5	0	0	71	
3	0	0	53	
0	0	10	72	
0	0	20	65	
1.5	0	10	20	
1.5	0	20	10	36
3	0	10	0	25
3	0	20	0	18
0	50	0	90	
0	100	0	84	
0	0	7.5	81	
0	0	15	66	
0	50	7.5	66	
0	100	7.5	64	71
0	50	15	51	65
0	100	15	32	56
0	150	0	32	50
0	0	15	77	
0	150	15	0	9

-25-

APPENDIX 2 - LITERATURE CITED

Adany, I., *et al.*, "Differences in sensitivity to farnesol toxicity between neoplastically- and non-neoplastically-derived cells in culture," *Cancer Lett.* 79:175-179, 1994.

American Institute of Nutrition. Report of the American Institute of Nutrition ad hoc committee on standards for nutritional studies. *J. Nutr.* 107:1340-1348, 1977.

Block, G., *et al.*, "Fruit, vegetables, and cancer prevention: A review of the epidemiological evidence," *Nutr. Cancer* 18:1-29, 1992.

Coni, P., *et al.*, "Hypomethylation of β -hydroxy- β -methylglutaryl coenzyme A reductase gene and its expression during hepatocarcinogenesis in the rat," *Carcinogenesis* 13:497-499, 1992.

Correll, C.C., *et al.*, "Identification of farnesol as the non-sterol derivative of mevalonic acid required for the accelerated degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase," *J. Biol. Chem.* 269:17390-17393, 1994.

Counts, J.L. and Goodman, J.I., "Hypomethylation of DNA: a possible epigenetic mechanism involved in tumor promotion," *Prog. Clin. Biol. Res.* 391:81-101, 1995.

Crane, D., "Biosynthesis of sesquiterpenes. In: Biosynthesis of Isoprenoid Compounds (Porter, J.W. and Spurgeon, S.L., eds.) vol. 1, pp. 283-374. John Wiley & Sons, New York, NY, 1981.

Croteau, R., "Biosynthesis of monoterpenes. In: Biosynthesis of Isoprenoid Compounds (Porter, J.W. and Spurgeon, S.L., eds.) vol. 1, pp. 225-282. John Wiley & Sons, New York, NY, 1981.

Crowell, P.L., *et al.*, "Selective inhibition of isoprenylation of 21-26-kDa proteins by the anticarcinogen d-limonene and its metabolites," *J. Biol. Chem.* 266:17679-17685, 1991.

Cuthbert, J.A. and Lipsky, P.E., "Suppression of the proliferation of ras-transformed cells by fluoromevalonate, an inhibitor of mevalonate metabolism," *Cancer Res.* 55:1732-1740, 1995.

DeClue, J.E., *et al.*, "Inhibition of cell growth by lovastatin is independent of ras function," *Cancer Res.* 51:712-717, 1991.

Elson, C.E., "Suppression of mevalonate pathway activities by dietary isoprenoids: Protective roles in cancer and cardiovascular disease," *J. Nutr.* 125:1666s- 1672s, 1995.

Elson, C.E. and Qureshi, A.A., "Coupling the cholesterol- and tumor-suppressive actions of palm oil to the impact of its minor constituents on 3-hydroxy-3-methylglutaryl coenzyme A

-26-

reductase activity," Prost. Leuko. Essen. Fatty Acid 52:205-208, 1995.

Elson, C.E. and Yu, S.G., "The chemoprevention of cancer by mevalonate-derived constituents of fruits and vegetables," J. Nutr. 124:607-614, 1994.

Gould, M.N., "Prevention and therapy of mammary cancer by monoterpenes," J. Cell. Biochem. S22:139-144, 1995.

Gould, M.N., et al., "A comparison of tocopherol and tocotrienol for the chemoprevention of chemically-induced mammary tumors," Am. J. Clin. Nutr. 53:1068S-1070S, 1991.

Greenberg, E.R. and Sporn, M.B., "Antioxidant vitamins, cancer and cardiovascular disease," New Engl. J. Med. 334:1189-1190, 1996.

Gruber, J.R., et al., "Increased expression of protein kinase C α plays a key role retinoic acid-induced melanoma differentiation," J. Biol. Chem. 267:13356-13360, 1992.

Haycock, K.A., et al., "Nonparametrics. In: StatView, pp. 344-355. Abaacus Concepts, Berkeley, CA, 1992.

Kamal-Eldin, A. and Appelqvist, L-A., "The chemistry and antioxidant properties of tocopherols and tocotrienols," Lipids 31:671-701, 1996.

Kawata, S., et al., "Increase in the active form of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human hepatocellular carcinoma: Possible mechanism for alteration of cholesterol biosynthesis," Cancer Res. 50:3270-3273, 1990.

Kohl, N.E., et al., "Development of inhibitors of protein farnesylation as potential chemotherapeutic agents," J. Cell. Biochem. 22:145-150, 1995.

Komiyama, K., et al., "Studies on the biological activity of tocotrienols," Chem. Pharm. Bull. 37:1369-1371, 1989.

Kuwashima, Y., et al., "Responses of a murine B16 melanoma to pharmacotherapy studied and compared with different assay systems," Cancer Res. Clin. Oncol. 116:173-178, 1990.

Laird, P.W. and Jaenisch, R., "DNA methylation and cancer," Human Molec. Gen. 3:1487- 1495, 1994.

Mac Neil, S., et al., "Signal transduction in murine B16 melanoma cells," Melanoma Res. 2:197-206, 1992.

Meadows, G.G., et al., "Ascorbate in the treatment of experimental transplanted melanoma," Am. J. Clin. Nutr. 54:1284s- 1291s, 1991.

-27-

Møeigs, T.E., *et al.*, "Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A degradation by the nonsterol mevalonate farnesol *in vivo*," *J. Biol. Chem.* 271:7916-7922.

Parker, R.A., *et al.*, "Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase," *J. Biol. Chem.* 268:11230-11238, 1993.

Perez-Sala, D. and Mollinedo, F., "Inhibition of isoprenoid biosynthesis induces apoptosis in human promylocytic HL-60 cells," *Biochem. Biophys. Res. Commun.* 199:1209-1215, 1994.

Qureshi, A.A., *et al.*, "Response of hypercholesterolemic subjects to administration of tocotrienols," *Lipids* 30:1171-1177, 1995.

Rossiello, M.R., *et al.*, "Similar patterns of hypomethylation in the β -hydroxy- β -methylglutaryl coenzyme A reductase gene in hepatic nodules induced by different carcinogens," *Molec. Carcinogenesis* 10:237-245, 1994.

Shoff, S.M., *et al.*, "Concentration-dependent increase in murine P388 and B16 population doubling time by the acyclic monoterpene geraniol," *Cancer Res.* 51:37-42, 1991.

Thibault, A., *et al.*, "Phase I study of phenylacetate administration twice daily to patients with cancer," *Cancer* 75:2932-2938, 1995.

Thibault, A., *et al.*, "Phase I studies of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer," *Clin. Cancer Res.* 2:483-491, 1996.

Tsukamoto, K., *et al.*, "Malignant melanoma: relationship to parameters of differentiation," *Melanoma Res.* 1:223-230, 1991.

Vasudevan, S., *et al.*, "Hypomethylation of β -hydroxy- β -methylglutaryl coenzyme A (HMG CoA) reductase gene in polyps and cancers of human colon," *FASEB J.* 8:A647, 1994 (abs.).

West, C., "Biosynthesis of diterpenes. In: Biosynthesis of Isoprenoid Compounds (Porter, J.W. and Spurgeon, S.L., eds.) vol. 1, pp. 375-411, John Wiley & Sons, New York, NY, 1981.

Yu, S.G., *et al.*, "Geraniol, an inhibitor of mevalonate biosynthesis, suppresses the growth of hepatomas and melanomas transplanted to rats and mice, *J. Nutr.* 125:2763-2767, 1995.

-28-

CLAIMS

I claim:

1. A method of inhibiting the growth of tumor cells comprising the step of exposing tumor cells to an effective amount of a composition comprising at least two compounds selected from the group consisting of tocotrienols, statins, 5 and ionones, wherein the amount is effective to inhibit tumor cell growth.
2. The method of claim 1 wherein the composition comprises a tocotrienol and an ionone.
3. The method of claim 1 wherein the composition comprises a tocotrienol and a statin.
4. The method of claim 1 wherein the composition comprises a statin and an ionone.
5. The method of claim 1 wherein the composition comprises a statin, an ionone and a tocotrienol.
6. The composition of claim 1 wherein the tocotrienol is selected from the group consisting of *d*- γ -tocotrienol, 2-desmethyltocotrienol, *d*- δ -tocotrienol and *d*-tocotrienol.
7. The method of claim 1 wherein the tocotrienol is *d*- γ -tocotrienol.
8. The method of claim 1 wherein the ionone is selected from the group consisting of β -ionone and α -ionone.
9. The method of claim 1 wherein the ionone is β -ionone.
10. The method of claim 1 wherein the statin is lovastatin.

SUBSTITUTE SHEET (RULE 26)

-29-

11. The method of claim 1 wherein the exposing step comprises administering the composition in the form of a food.

12. The method of claim 1 wherein the exposing step comprises administering the composition in the form of a pharmaceutical.

13. A method of inhibiting tumor growth comprising the step of exposing a patient to an effective amount of a composition comprising at least two compounds selected from the group consisting of tocotrienols, statins and ionones, 5 wherein the amount is effective to inhibit tumor growth.

14. A pharmaceutical composition comprising an effective amount of at least two compounds selected from the group consisting of tocotrienols, statins and ionones wherein the amount is effective to inhibit tumor growth.

15. The pharmaceutical composition of claim 14 comprising at least one tocotrienol and at least one ionone.

16. The pharmaceutical composition of claim 14 comprising at least one tocotrienol and at least one statin.

17. The pharmaceutical composition of claim 14 comprising at least one statin and at least one ionone.

18. The pharmaceutical composition of claim 14 comprising at least one statin, at least one ionone and at least one tocotrienol.

19. The pharmaceutical composition of claim 14 comprising β -ionone and d - γ -tocotrienol.

20. The composition of claim 14 wherein the composition is part of a food.

SUBSTITUTE SHEET (RULE 26)

-30-

21. The composition of claim 14 wherein the daily intake of tocotrienol is between 250 mg and 500 mg.

22. The composition of claim 14 wherein the daily intake of ionone is between 2000 mg and 4000 mg.

23. The composition of claim 14 wherein the daily intake of statin is between 150 mg and 300 mg.

24. The composition of claim 18 wherein the daily intake of tocotrienol is between 250 mg and 500 mg, of ionone is between 200 mg and 400 mg and of statin is between 150 mg and 300 mg.

SUBSTITUTE SHEET (RULE 26)

1/4




FIG. 1

2/4




FIG. 2A

3/4




FIG. 2B

4/4




FIG. 3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/03470

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/355 A61K31/35

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K A23L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ELSON: "Novel Lipids and Cancer: Isoprenoids and Other Phytochemicals" ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, vol. 399, 1996, pages 71-86, XP002067388 see page 71; figures 1-4 see page 75-76; table 1 see page 78, paragraph 3-4 see page 79, paragraph 3	1,2,6-9, 11-15, 19,20
A	US 5 591 772 A (LANE RONALD H ET AL) 7 January 1997 see column 3, line 35-44; examples 19,20 see column 17, line 62 - column 18, line 7; claims 1,12,16	5,10,18
X	---	1,3,6, 10-14, 16,20-23
	---	-/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

9 June 1998

Date of mailing of the international search report

02.07.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Kanbier, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/03470

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 93 20183 A (ZEAGEN INC) 14 October 1993 see page 3, line 11-13; claims 13,15 see page 10, line 18-27 see page 11, line 1-20 ---	14,17
X	WO 93 16690 A (WARNER LAMBERT COMPANY) 2 September 1993 see column 16, line 20-34; claims 1,3,6 see column 54, line 7-11 ---	14,16,20
A	US 5 605 930 A (SAMID DVORIT) 25 February 1997 see column 4, line 56 - column 5, line 30 see column 10, line 4-9 see column 20, line 3-11 ---	1,3,4, 10, 12-14, 16,17
A	WO 93 23034 A (US ARMY) 25 November 1993 see page 4, line 18-23; claims 1,2,11,15,20,22 ---	1,3,10, 12,13
A	EP 0 382 075 A (BASF AG) 16 August 1990 see column 1, line 45-50; claims 1,8 see column 4, line 15-35 ---	1,2,4,5, 9,12,13
A	US 5 376 361 A (PERRICONE NICHOLAS V) 27 December 1994 see column 7, line 28-32; claim 1 -----	1-3,5-7, 12,13

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 98/03470

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-13 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/03470

Patent document cited in search report	Publication date	Patent family member(s)		Publication date	
US 5591772	A	07-01-1997	AU AU CA CN EP JP MX NO WO	670557 B 3150293 A 2124086 A 1073357 A 0543417 A 7504887 T 9206735 A 941929 A 9309777 A	25-07-1996 15-06-1993 27-05-1993 23-06-1993 26-05-1993 01-06-1995 01-05-1993 13-07-1994 27-05-1993
<hr/>					
WO 9320183	A	14-10-1993	AU US	3919193 A 5422247 A	08-11-1993 06-06-1995
<hr/>					
WO 9316690	A	02-09-1993	AU AU CA EP JP MX US ZA	3315397 A 4275793 A 2129732 A 0627917 A 7505145 T 9301014 A 5633285 A 9301297 A	30-10-1997 13-09-1993 02-09-1993 14-12-1994 08-06-1995 01-09-1993 27-05-1997 27-06-1994
<hr/>					
US 5605930	A	25-02-1997	US AU CA EP JP WO US US US US US US US US US ZA AU CA EP NZ WO	5635532 A 7973794 A 2173976 A 0725635 A 9506079 T 9510271 A 5708025 A 5712307 A 5654333 A 5661179 A 5710178 A 5635533 A 9407964 A 2804592 A 2108963 A 0567613 A 244850 A 9307866 A	03-06-1997 04-05-1995 20-04-1995 14-08-1996 17-06-1997 20-04-1995 13-01-1998 27-01-1998 05-08-1997 26-08-1997 20-01-1998 03-06-1997 06-03-1996 21-05-1993 22-04-1995 03-11-1993 29-01-1997 29-04-1993

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l Application No

PCT/US 98/03470

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 5605930	A	ZA	9208140 A	21-04-1994

WO 9323034	A	25-11-1993	AU 683839 B AU 4244393 A CA 2135312 A EP 0642341 A JP 8503451 T	27-11-1997 13-12-1993 25-11-1993 15-03-1995 16-04-1996

EP 0382075	A	16-08-1990	DE 3903991 A AU 617923 B AU 4926490 A CA 2007933 A DE 59005487 D DK 382075 T JP 3197455 A MX 9203498 A US 5041648 A	30-08-1990 05-12-1991 16-08-1990 10-08-1990 01-06-1994 24-05-1994 28-08-1991 01-08-1992 20-08-1991

US 5376361	A	27-12-1994	US 5545398 A	13-08-1996
